All articles tagged with #drug prices
Colorado has FDA approval to import 20 prescription drugs from Canada, including Ozempic and Eliquis, in a bid to lower costs—potentially 20–70% cheaper per drug and about $46 million in savings over three years—though availability will depend on Canada’s supply and manufacturers’ participation; safety and supply-chain concerns persist, and Florida is the only other state with a similar approval.
Drugmakers and insurers have stepped up campaigns to blame hospitals for high U.S. health-care costs, aiming to curb the 340B drug-discount program and push site-neutral policies as lawmakers consider Medicare pay cuts and tighter regulation. Hospitals counter that mergers, rising drug costs, and administrative burdens drive prices, and are increasing lobbying and messaging to defend their position while policy changes—backed by the Trump administration and Congress—loom, including potential restructuring of 340B and scrutiny of hospital consolidations.
Trump’s drug-pricing efforts have yielded uneven gains: Medicare's negotiated discounts cut some prices and cap out-of-pocket costs, and TrumpRx offered notable cuts on certain brand drugs, but overall about 1,000 branded drugs rose in price in early 2026, and benefits mostly reach cash-paying patients, with many discounts opaque and limited in scope; experts say the policy changes do not broadly reshape drug pricing.
President Trump announced the first round of private drug-pricing deals with Regeneron, including Medicaid price reductions, a $225 price for Praluent under TrumpRx, and a $27 billion U.S. investment in drug development; Regeneron also disclosed FDA approval of Otarmeni under a National Priority Voucher program and plans to provide it at no cost to American patients, signaling affordability efforts, though critics say the overall impact has fallen short of promises and the Otarmeni development has faced Deaf-community pushback.
At a White House event on health-care affordability, President Trump defended his drug-price figures by citing 'two ways of calculating'—a move critics say relies on mathematically inconsistent math, as CMS official Chris Klomp and Health and Human Services Secretary Robert Kennedy Jr. listened.
President Trump visited Reading, Ohio, touring Thermo Fisher and promoting U.S. manufacturing and efforts to lower prescription drug costs, while defending his energy record; he discussed potential use of the Strategic Petroleum Reserve to ease gas prices, urged voter ID and opposed mail-in voting, and framed the Cincinnati trip as both policy work and a campaign moment ahead of the midterms.
President Trump launched TrumpRx.gov to offer steep discounts on 40 high-cost medicines by tying U.S. prices to MFN prices paid in other developed nations. The rollout includes drugs from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, with additional products to follow. Patients with prescriptions can access savings via printable or mobile coupons or through manufacturer channels integrated into TrumpRx.gov. Notable examples include large price cuts for diabetes, obesity, fertility, COPD, asthma, and insulin, such as Ozempic, Wegovy, Zepbound, Gonal-F, Cetrotide, Ovidrel, and insulin lispro. The move builds on prior executive orders and agreements aimed at lowering prices and reforming how American drug costs are set.
President Trump pitches the Great Healthcare Plan to Congress to lower drug prices via Most-Favored-Nation pricing, reduce insurance premiums by ending subsidy payments and funding cost-sharing reductions, curb PBM kickbacks, and boost price transparency with plain-English disclosures, posted costs, and expanded over-the-counter access, including direct payments to Americans.
President Trump unveils The Great Healthcare Plan, promising to lower costs by slashing prescription prices, reducing insurance premiums by redirecting subsidies to individuals, expanding funding for cost-sharing reductions, and enforcing price transparency from insurers and providers, including publishing prices and denial rates to empower consumers.
Trump called on Congress to enact The Great Healthcare Plan to lower drug prices (via MFN pricing), slash insurance premiums, curb PBM kickbacks, and boost price transparency with plain-English disclosures so Americans can compare costs and hold insurers accountable, building on his prior executive actions.
Johnson & Johnson has reached an agreement with the US government to lower drug prices for Americans in exchange for tariff exemptions, participating in initiatives to make medicines more affordable and building new manufacturing facilities in the US as part of a broader investment plan.
Johnson & Johnson has reached an agreement with the U.S. government to lower drug prices for Americans in exchange for tariff exemptions, participating in discounted drug sales and expanding manufacturing investments in the U.S.
Drugmakers plan to raise prices on at least 350 medicines in the U.S., including vaccines and cancer treatments, despite pressure from the Trump administration to lower costs, with some drugs also seeing significant price cuts. The increases are part of ongoing strategies to maximize profits amid regulatory and political scrutiny, while some companies adjust prices to keep pace with inflation and support innovation.
Drugmakers plan to raise prices on at least 350 medicines in the US for 2026, including vaccines and cancer treatments, despite pressure from the Trump administration to lower costs. While some drugs will see price cuts, overall prices are increasing, with companies like Pfizer and GSK citing the need to support innovation and cover costs. These hikes occur even as the US continues to pay significantly more for prescription drugs compared to other developed nations.
The article argues that high drug prices in the US are primarily due to pharmaceutical companies charging what the market can bear, not foreign countries paying less, and criticizes Trump's approach of blaming international partners instead of addressing systemic issues within the US pharmaceutical industry and global trade policies that favor profits over access to medicines.